$15.16
-0.51-3.25%
Last update: Oct 30, 5:24 PM
Mesoblast Ltd (MESO) Stock Price, Quote, News & History
MESONASDAQ
Glaukos surged 17.4% premarket after strong Q3 results and raised FY26 sales guidance; INLF, NCPL and PCLA also rallied.
You can purchase shares of Mesoblast (NASDAQ:MESO) through any online brokerage.
Other companies in Mesoblast’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Mesoblast has a consensus price target of $25.50.
The stock price for Mesoblast (NASDAQ: MESO) is $15.3 last updated October 30, 2026 at 5:24 PM EDT.
There are no upcoming dividends for Mesoblast.
Mesoblast does not have any upcoming earnings scheduled.
There is no upcoming split for Mesoblast.
Mesoblast is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is...
